C07K 2319/715
Containing a domain for ligand dependent transcriptional activation
Official title: containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
C07K2319/715 (Containing a domain for ligand dependent transcriptional activation) appears on 92 US grants and 97 published applications in this corpus.
Search patents in C07K- Granted patents
- 92
- Published applications
- 97
- Assignees
- 63
- Inventors
- 204
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 4 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 7 | 0 |
| 1997 | 2 | 0 |
| 1998 | 5 | 0 |
| 1999 | 8 | 0 |
| 2000 | 7 | 0 |
| 2001 | 5 | 0 |
| 2002 | 0 | 3 |
| 2003 | 3 | 1 |
| 2004 | 1 | 3 |
| 2005 | 2 | 0 |
| 2006 | 5 | 3 |
| 2007 | 0 | 3 |
| 2008 | 0 | 2 |
| 2009 | 0 | 5 |
| 2010 | 3 | 2 |
| 2011 | 1 | 5 |
| 2012 | 3 | 5 |
| 2013 | 2 | 4 |
| 2014 | 5 | 2 |
| 2015 | 0 | 0 |
| 2016 | 4 | 2 |
| 2017 | 1 | 3 |
| 2018 | 0 | 4 |
| 2019 | 0 | 2 |
| 2020 | 0 | 3 |
| 2021 | 2 | 5 |
| 2022 | 2 | 15 |
| 2023 | 3 | 7 |
| 2024 | 4 | 3 |
| 2025 | 5 | 8 |
| 2026 | 5 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Regulated synthetic gene activation systems18 Aug 2026US 12,709,637 B2Trustees of Boston University
- Engineered immune cells with micro-clusters7 Apr 2026US 12,595,291 B2A2 Biotherapeutics, Inc.
- Caged-degron-based molecular feedback circuits and methods of using the same24 Mar 2026US 12,583,896 B2The Regents of the University of California
- Regulated synthetic gene expression systems24 Feb 2026US 12,559,530 B2Trustees of Boston University
- Engineered immune cells with receptor cross-talk27 Jan 2026US 12,534,509 B2A2 Biotherapeutics, Inc.
- Synthetic notch receptors for use in customized spatial control of multiple gene expressions and uses thereof1 Oct 2026US 2026/0297539 A1The Regents of the University of California
- Self-assembling systems for modeling intracellular protein aggregation10 Sep 2026US 2026/0265322 A1
- Engineered immune cells with receptor cross-talk6 Aug 2026US 2026/0226135 A1A2 Biotherapeutics, Inc.
- Engineered immune cells with receptor signal strength modulated by a hinge16 Jul 2026US 2026/0201012 A1A2 Biotherapeutics, Inc.
- Engineered immune cells with micro-clusters16 Jul 2026US 2026/0201014 A1A2 Biotherapeutics, Inc.
Most cited
By later US patents
- Retinoic acid receptor method226US 4,981,784 AThe Salk Institute for Biological Studies · 1991
- Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins194US 5,977,307 AAlkermes, Inc. · 1999
- Transferrin neuropharmaceutical agent fusion protein150US 5,672,683 AAlkermes, Inc. · 1997
- Transferrin receptor specific antibody-neuropharmaceutical agent conjugates141US 5,527,527 AAlkermes, Inc. · 1996
- Regulated apoptosis125US 5,834,266 APresident and Fellows of Harvard College · 1998